Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2006
gptkb:FDA |
| gptkbp:atccode |
L01 XE03
|
| gptkbp:brand |
gptkb:Sutent
|
| gptkbp:casnumber |
557795-19-4
|
| gptkbp:chemical_formula |
C22 H26 FN3 O2
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to sunitinib |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:excretion |
urine
|
| gptkbp:financial_support |
do not crush or chew tablets
take with or without food stay hydrated during treatment report any signs of bleeding avoid grapefruit products |
| gptkbp:formulation |
gptkb:tablet
gptkb:capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
sunitinib
|
| gptkbp:indication |
gptkb:hepatocellular_carcinoma
gptkb:Oncology neuroendocrine tumors pancreatic neuroendocrine tumors |
| gptkbp:interacts_with |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:is_monitored_by |
blood pressure
liver function tests complete blood count thyroid function tests |
| gptkbp:lifespan |
40-60 hours
|
| gptkbp:mechanism_of_action |
tyrosine kinase inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
gptkb:anemia
fatigue nausea hypertension diarrhea thromboembolic events cardiovascular events hypothyroidism skin rash thrombocytopenia stomatitis leukopenia |
| gptkbp:storage |
room temperature
protected from light protected from moisture |
| gptkbp:targets |
gptkb:VEGFR
gptkb:PDGFR KIT |
| gptkbp:used_for |
treatment of gastrointestinal stromal tumors
treatment of renal cell carcinoma |
| gptkbp:weight |
398.47 g/mol
|
| gptkbp:bfsParent |
gptkb:gastrointestinal_stromal_tumors
gptkb:KIT_mutations |
| gptkbp:bfsLayer |
6
|